Thermo Fisher Scientific Inc. (TMO) Shares Bought by Bank of The Ozarks

Bank of The Ozarks boosted its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.8% during the fourth quarter, Holdings Channel reports. The fund owned 7,601 shares of the medical research company’s stock after buying an additional 275 shares during the quarter. Bank of The Ozarks’ holdings in Thermo Fisher Scientific were worth $1,443,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Bank of Nova Scotia Trust Co. bought a new position in shares of Thermo Fisher Scientific during the 3rd quarter valued at about $106,000. Ropes Wealth Advisors LLC increased its position in shares of Thermo Fisher Scientific by 15.8% during the 2nd quarter. Ropes Wealth Advisors LLC now owns 710 shares of the medical research company’s stock valued at $124,000 after purchasing an additional 97 shares during the last quarter. Atlantic Trust LLC bought a new position in shares of Thermo Fisher Scientific during the 2nd quarter valued at about $138,000. Acrospire Investment Management LLC increased its position in shares of Thermo Fisher Scientific by 66.7% during the 2nd quarter. Acrospire Investment Management LLC now owns 1,000 shares of the medical research company’s stock valued at $174,000 after purchasing an additional 400 shares during the last quarter. Finally, Glassman Wealth Services increased its position in shares of Thermo Fisher Scientific by 23.1% during the 2nd quarter. Glassman Wealth Services now owns 1,039 shares of the medical research company’s stock valued at $181,000 after purchasing an additional 195 shares during the last quarter. Institutional investors and hedge funds own 86.31% of the company’s stock.

Several equities analysts have recently commented on TMO shares. Zacks Investment Research upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $215.00 price objective on the stock in a research report on Tuesday, October 31st. Leerink Swann reiterated an “outperform” rating and set a $200.00 price objective (down from $216.00) on shares of Thermo Fisher Scientific in a research report on Monday, December 4th. Evercore ISI started coverage on Thermo Fisher Scientific in a research report on Wednesday, January 3rd. They set an “outperform” rating and a $220.00 price objective on the stock. Deutsche Bank set a $226.00 price objective on Thermo Fisher Scientific and gave the company a “buy” rating in a research report on Thursday, October 26th. Finally, BTIG Research started coverage on Thermo Fisher Scientific in a research report on Friday, January 5th. They set a “buy” rating and a $230.00 price objective on the stock. Two investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. Thermo Fisher Scientific has a consensus rating of “Buy” and an average price target of $220.50.

In related news, SVP Gregory J. Herrema sold 33,327 shares of the stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $219.70, for a total transaction of $7,321,941.90. Following the completion of the sale, the senior vice president now directly owns 60,471 shares in the company, valued at approximately $13,285,478.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Marc N. Casper sold 50,000 shares of the stock in a transaction dated Wednesday, November 15th. The shares were sold at an average price of $188.39, for a total value of $9,419,500.00. Following the sale, the chief executive officer now owns 252,577 shares of the company’s stock, valued at $47,582,981.03. The disclosure for this sale can be found here. Insiders have sold a total of 133,327 shares of company stock valued at $26,328,442 over the last 90 days. 0.49% of the stock is currently owned by company insiders.

Shares of Thermo Fisher Scientific Inc. (TMO) opened at $209.48 on Wednesday. The firm has a market capitalization of $83,560.00, a PE ratio of 37.41, a P/E/G ratio of 1.59 and a beta of 1.11. Thermo Fisher Scientific Inc. has a fifty-two week low of $151.69 and a fifty-two week high of $226.44. The company has a current ratio of 1.35, a quick ratio of 0.92 and a debt-to-equity ratio of 0.74.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, January 31st. The medical research company reported $2.79 earnings per share for the quarter, beating the consensus estimate of $2.66 by $0.13. The company had revenue of $6.05 billion during the quarter, compared to analysts’ expectations of $5.72 billion. Thermo Fisher Scientific had a return on equity of 16.01% and a net margin of 10.64%. Thermo Fisher Scientific’s quarterly revenue was up 22.1% compared to the same quarter last year. During the same period in the prior year, the business posted $2.41 EPS. equities analysts predict that Thermo Fisher Scientific Inc. will post 10.81 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Monday, April 16th. Investors of record on Thursday, March 15th will be issued a dividend of $0.17 per share. The ex-dividend date of this dividend is Wednesday, March 14th. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.15. This represents a $0.68 annualized dividend and a yield of 0.32%. Thermo Fisher Scientific’s dividend payout ratio is currently 10.71%.

WARNING: This report was first published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another domain, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this report can be accessed at https://www.com-unik.info/2018/02/07/thermo-fisher-scientific-inc-tmo-shares-bought-by-bank-of-the-ozarks.html.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit